Baxter launches global sales of Theranova
DEERFIELD - Baxter International has launched the global sale HDx enabled by Theranova, a new type of hemodialysis therapy that provides high performance treatments with integration into existing health care infrastructure.
Baxter will launch HDx enabled by Theranova in Australia, New Zealand, France, Germany, Switzerland and Belgium this year.
HDx, or expanded hemodialysis, uses Baxter's new Theranova dialyzer to extend the range of molecules that can be filtered from the blood during therapy, resulting in a filtration profile that more closely mimics the natural kidney. 1 Theranova dialyzers are indicated for treatment of chronic and acute renal failure by hemodialysis.
"Through HDx enabled by Theranova, Baxter is introducing a major advancement in hemodialysis, an area that has seen little improvement in recent years," said Giuseppe Accogli, corporate vice president and president of Baxter Renal. "We expect HDx enabled by Theranova to advance hemodialysis care for millions of patients around the world."